You are here: Industry Insights > Humanigen

News List

Humanigen and Cenexi Collaborate to Manufacture Lenzilumab in France contractpharma
February 09, 2022
CDMO Cenexi to become preferred drug product supplier for France and the EU.
Humanigen starts rolling submission for Covid-19 drug in UK pharmaceutical-technology
June 15, 2021
Humanigen has commenced a rolling review submission to the UK Medicines and Healthcare Products Regulatory Agency (MHRA), seeking marketing approval for its drug candidate, lenzilumab.
Humanigen seeks EUA from USFDA for Lenzilumab to treat COVID-19 expresspharma
May 31, 2021
This EUA application follows positive results from the LIVE-AIR Phase 3 clinical trial evaluating the ability of lenzilumab to improve the likelihood of survival without ventilation (SWOV) in newly hospitalised COVID-19 patients.
Humanigen Selects Chime Biologics as Manufacturing Partner contractpharma
May 18, 2021
Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, and Chime Biologics, a contract development and manufacturing ...
Humanigen’s lenzilumab improves survival in hospitalised Covid-19 patients pharmaceutical-technology
March 30, 2021
Humanigen has reported that its phase III clinical trial of its lead drug candidate, lenzilumab, showed improvement in the relative likelihood of survival in hospitalised Covid-19 patients.
Avid, Humanigen Enter Lenzilumab Mfg. Agreement contractpharma
February 04, 2021
Avid Bioservices, Inc. and Humanigen, Inc. have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigen’s therapeutic candidate in development for COVID-19.
Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement contractpharma
January 28, 2021
Ajinomoto will support fill finish for investigational COVID-19 therapeutic, lenzilumab, nearing completion of phase 3 study.
Humanigen, Emergent Enter Covid-19 Partnership contractpharma
January 26, 2021
Sign contract development and manufacturing agreement for Phase 3 COVID-19 therapeutic candidate lenzilumab.
Humanigen, EVERSANA to partner for launch, commercialisation of Lenzilumab for COVID-19 treatment expresspharma
January 11, 2021
Lenzilumab, a monoclonal antibody, is designed to prevent and treat cytokine storm, a complication considered to be a leading cause of COVID-19 death.
Humanigen signs Covid-19 therapy development deal with US pharmaceutical-technology
November 10, 2020
Humanigen has signed an agreement with the US Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop lenzilumab for Covid-19 treatment.

Previous page 1 2 Next page